Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: (TSXV:
$KHRN.V) (CSE: $DIXI_U.C) (OTCQX: $DXBRF) (CSE: $CBDT.C) (TSX: $TGOD.TO)
Delta, Kelowna, BC –August
7, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news
source covering leading sectors including marijuana and hemp stocks and its
potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and
experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2019/cannabis-potcasts/08071KHRN-DIXI-DXBRF-CBDT-TGOD.asp
In
today’s podcast we look at a few early announcements.
But
first, Strainprint™ Technologies Ltd. has launched the next stage of the much-anticipated clinical trial
with Israeli based research group Gynica
to develop a product formulation to treat endometriosis and its symptoms. This
phase will include asking endometriosis sufferers in Canada and Israel to
complete an anonymous, comprehensive custom questionnaire about how they use
cannabis to treat their symptoms.
Strainprint, the leader in cannabis data
and analytics partnered with Israeli researchers at Gynica, a leader in
cannabis-based solutions for women's health, in late 2018 to conduct the
world's first international clinical study on the use of cannabis to treat
endometriosis. The study will leverage Strainprint's database of patient
reported outcomes among those who use cannabis to treat endometriosis, which,
along with the results of this questionnaire will inform the formulation of a
cannabis-based product which will be clinically validated and then available
for purchase.
Endometriosis affects approximately 1 in 10
women and it is a condition with limited understanding and treatment options.
“180 million people worldwide experience
severe pain daily as a result of tissue similar to the uterine lining migrating
to other organs inside the body, causing debilitating pain, infertility,
fatigue, gastrointestinal and/or bladder symptoms," says Gynica's
Professor Moshe Hod, President of the European Association of Perinatal
Medicine and Professor of Obstetrics and Gynecology at Tel Aviv University
medical school. "Our objective is to recruit suffering candidates to
explore cannabis as a viable therapy in the hopes of developing improved
diagnostics and treatments to those who are undertreated by current
solutions."
"We believe many women will be eager
to take part in this ground-breaking research," says Michelle Arbus,
Strainprint's VP of Research. "Our online Strainprint Community already
provides a safe space to discuss endometriosis and cannabis treatment with
fellow sufferers, and through this questionnaire, participants will have the
opportunity to contribute to research and play a more active role in their
healthcare with alternative methods not yet explored. Some of these
endometriosis sufferers have dealt with excruciating pain for many years and do
not tolerate or respond to the current treatment options available. They will
now have a chance to be pioneers in a study that could make medical history by
helping others not only manage their symptoms, but also greatly improve their
quality of life."
Survey participants must be 18 years or
older and currently suffer from endometriosis. Once they register to the
Strainprint Community, they can request access to an exclusive group, only open
to questionnaire participants, giving them access to the questionnaire, forums,
specialized endometriosis education materials and more.
Here is how interested candidates can
participate:
- Go to https://strainprint.ca/community/groups/endometriosis/
- Click Join the Community or already a member? login here
- You'll be returned to the Endometriosis Group where
you'll click request membership.
- Once your group membership has been approved, and you
enter the group, click on the survey link.
Once this phase of the study is complete,
respondents from both Canada and Israel will be asked if they would like to
participate in a clinical trial of a cannabis-based therapy.
Khiron
Life Sciences Corp. (TSXV: KHRN)(OTCQB: KHRNF) announced today that it has signed a distribution
agreement for its Kuida cosmeceutical brand with Grupo Éxito, Colombia´s market
leading retail group and one of the largest retailers in South America.
Grupo Éxito is a Colombian retailer with a
successful 110-year presence in the Latin American market and is the only
retail company in the region included in the Dow Jones Sustainability index,
under the "Emerging Markets" category. Controlled by Casino
Guichard-Perrachon and with revenues of U.S.$17 billion in 2018, Grupo Éxito
operates 1,533 stores across Colombia, Uruguay, Brazil and Argentina, including
252 Éxito stores and 9 Éxito WOW stores. Under the Company's agreement with
Grupo Éxito, Kuida will initially be sold in 5 Éxito WOW stores and 16
traditional format stores.
Introduced by Grupo Éxito in 2018, Éxito
WOW represents a new store format aimed at delivering innovative,
digitally-integrated customer experiences throughout the Cali, Bogotá, Medellín,
and Barranquilla regions of Colombia among others. On introduction to Éxito WOW
stores, Kuida will form a cornerstone product line for the retailer's cannabis
products category. To support Kuida sales and brand awareness, each Éxito WOW
location will host dedicated experience centres, with skin expert consultants
on-hand to educate consumers on the brand's proprietary CBDERM technology, as
well as its current portfolio of seven skin and personal care products.
Khiron Life Sciences Corp. and Dixie
Brands Inc. (CSE: DIXI.U) (OTCQX: DXBRF)
also announced that their previously disclosed 50/50
Joint Venture has received conditional approval from the TSX Venture
Exchange. With this approval in place,
Khiron and Dixie will begin the process of commercialization of the Kuida
cosmeceutical product line in the U.S. marketplace, as well as the introduction
of Dixie's CBD-infused products into Latin America.
Through
the JV, Dixie will be responsible for the distribution of Khiron's portfolio of
Kuida cosmeceutical products in the U.S.
Kuida products will be broadly distributed through Dixie's established
distribution network to U.S. consumers, and are expected to have particular
appeal to the growing U.S. Hispanic population, estimated at nearly 60 million.
Further,
the conditional TSXV approval allows for the manufacture and commercialization
of Dixie's products in Latin America, leveraging Khiron's legislative, sales
and marketing abilities and Dixie's extensive and market-proven product line.
It is anticipated that Dixie CBD-based products will be commercialized in Latin
America beginning in 2020. The JV also
creates a framework for the development of new products and brands tailored to
Latin America, allowing Dixie and Khiron to take full advantage of
opportunities resulting from advancements in cannabis legalization in the
region. The conditional TSXV approval covers operations in Colombia, Chile and
Uruguay; additional applications will be made to the TSXV as more Latin
American countries legalize the use of cannabis.
Alvaro
Torres, Khiron CEO and Director, comments: "With a strong JV leadership,
sales and marketing team in place, this regulatory approval positions us to
accelerate activities in both our core Latin American markets and in the
U.S. Bringing the full Kuida product
line to U.S. consumers is an important development as we build capacity and
market access to expand Kuida brand distribution into new jurisdictions
globally."
Dixie Brands Inc. and AriZona,
maker of the #1 selling iced tea in America, also announced signing a binding letter of intent on
Friday, August 2nd, 2019, to partner for the production,
distribution and sale of cannabis-infused products containing THC.
Under
the terms of this deal between Dixie Brands Inc., and the AriZona™ brand,
through its affiliated entity, Herbal Enterprises, LLC, will direct brand and
product conceptual design; while Dixie Brands will develop, formulate,
manufacture and distribute the new portfolio of AriZona branded THC infused
consumer packaged goods.
"AriZona
has always led the way in product innovation," said Don Vultaggio,
Chairman, AriZona Beverages. "The cannabis market is an important emerging
category, and we've maintained our independence as a private business to be
positioned to lead and seize generation-defining opportunities exactly like
this one. The Cannabis category is an ideal space to bring the flavor and fun
of AriZona into new and exciting products, and we selected Dixie Brands as our
partner to bring these products to market after touring their best in class
manufacturing facilities, and spending considerable time building a strong
relationship with their management. Both companies share a heritage of quality,
excellence in manufacturing, and doing things the right way, and we look
forward to all this partnership has in store."
"AriZona
is a power brand," said Chuck Smith, CEO Dixie Brands, "and the most
iconic and recognized CPG brand to extend into the cannabis market, providing
the evolving cannabis consumer with a fun and flavorful experience alongside an
iconic brand they know and love. For nearly a decade Dixie Brands has crafted
award-winning cannabis-infused products creating some of the most recognized and
trusted brands in the industry, and we are thrilled to have found a partner
that shares our values. This partnership marks a watershed moment for the
popularization and expansion of the cannabis sector overall, and is another
large step forward for Dixie Brands' strategy to build a house of famous
cannabis CPG brands."
EMPOWER CLINICS
INC. (CSE: CBDT) (OTC: EPWCF) announced that it has entered into a strategic
partnership with Endocanna Health Inc., a research and development
biotechnology company specializing in endocannabinioid DNA testing, and a
partly owned subsidiary of Heritage
Cannabis (CSE: CANN).
Endocanna
will manufacture its patent-pending Endocannabinoid DNA Test Kits for and
license its proprietary DNA technology to Empower. Empower will immediately
make the Endocanna kits available to its corporate owned medical clinics that
include 165,000 patients in Oregon, Arizona, Washington State and Nevada. The
Company plans to include the DNA Test Kits as a standard offering in the Sun
Valley Health franchise program, and has commenced it's roll-out in the United
States.
"We
continue to focus our initiatives on patient care and wellbeing, ensuring we
have the ability to provide best-in-class care and advice using the most
advanced technology available." said Steven McAuley, Empowers Chairman
& CEO. "The Endocanna DNA Test Kit can give our physicians the
potential to have even greater insight into each individual patient's
propensity for success, on how CBD based therapies may interact with their
individual regulatory system."
The
Kits are designed to provide consumers with personalized data about how
cannabidiol (CBD) and other cannabinoids may interact with their body, plus the
technology may allow the company to provide patients with science-backed
cannabis product suggestions based on their specific DNA.
"Using
Endocanna Health's proprietary DNA report, we can personalize and provide a
cannabinoid wellness protocol tailored to an individual's needs." said Len
May, CEO & Co-Founder of Endocanna Health. "Empower and their Sun Valley
Health clinic network, provides an immediate opportunity for us to work with
physicians and patients to develop advanced science surrounding the
endocannabinioid system and CBD based therapies."
The Green Organic
Dutchman Holdings Ltd. (TSX:TGOD) (OTC:TGODF) announced that it has submitted an application to
list its common shares on the NASDAQ.
The
listing of TGOD's shares on the NASDAQ will be subject to a number of
regulatory requirements, including registration of the common shares under the
U.S. Securities Exchange Act of 1934 and a determination by the NASDAQ that
TGOD has satisfied all applicable listing requirements. Subject to approval for listing, the common
shares will continue to trade on the TSX Exchange (TSX) under 'TGOD', which is
also the reserved symbol for the NASDAQ application.
"This
is an important step in the growth of TGOD, one that will broaden our investor
base and increase access for international investors as we build the leading
global organic cannabis brand,'' commented Brian Athaide, CEO of TGOD.
"Our team remains focused on executing our business plan and creating
value for our shareholders."
Alimentation
Couche-Tard Inc. (TSX: ATD.A) (TSX: ATD.B) and
Fire & Flower Holdings Corp. (TSX: FAF) today confirmed the closing of their transaction
previously announced on July 24, 2019. In addition, the common shares in the
capital of Fire & Flower commenced trading on the Toronto Stock Exchange as
of August 7, 2019.
The
Transaction includes the issuance today by Fire & Flower of an 8.0%
unsecured convertible debenture to an indirect wholly-owned subsidiary of
Couche-Tard in the aggregate principal amount of approximately $26.0M, which
principal amount of debenture is convertible by the Investor into 24,289,706
Common Shares at a price of $1.07 per Common Share, representing a 9.9%
ownership interest in Fire & Flower on a pro forma fully-diluted basis. The
Investor has also been issued Common Share purchase warrants that, if exercised
in full in accordance with the terms thereof, will subsequently increase the
Investor's ownership interest to 50.1% of Fire & Flower on a pro forma
fully-diluted basis.
In
connection with the closing of the Transaction, Fire & Flower announced the
appointment of Jeremy Bergeron as Couche-Tard's initial nominee to Fire &
Flower's board of directors.
"Through
this strategic investment, we reinforce our intention to become a key player in
North America's cannabis industry," said Brian Hannasch, President and CEO
of Couche-Tard. "We are excited to see what we can achieve together with
Fire & Flower, as we further expand in Canada and look to leverage our
presence in the United States and beyond."
"Combining
Couche-Tard's expertise in scaling retail stores with Fire & Flower's
retail experience and proprietary HifyreTM digital platform
positions our company extremely well to capitalize on new cannabis markets as
they emerge," added Trevor Fencott, Fire & Flower's Chief Executive
Officer.
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement
to buy products or services or securities. Investors are reminded all
investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also
available on iTunes, Spotify, Google
Play Music, Stitcher, Spreaker, YouTube
via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news
source publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play
by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI
Eye Podcast and column covering developments in
AI.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently compensated
for news publication and distribution, social media and marketing, content
creation and more. Disclosure is posted for each compensated news release,
content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where
permissible by law. Our site does not possess, distribute, or sell cannabis
products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
